[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"thyroid-papillary-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:thyroid-papillary-carcinoma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100621916","radiofrequency-ablation-for-curative-treatment-of-small-low-risk-papillary-thyroid-cancer-pilot-study-100621916",false,"NCT07376837","Radiofrequency Ablation for Curative Treatment of Small Low-Risk Papillary Thyroid Cancer: Pilot Study","Evaluating the Feasibility, Safety and Efficacy of Radiofrequency Ablation (RFA) for Curative Treatment of Small Low-Risk Thyroid Papillary Cancer: A Pilot Single Arm Clinical Trial","PTC-RFA","Inclusion criteria:\n\n* Histologically confirmed papillary thyroid carcinoma (PTC) by fine-needle aspiration (FNA -Bethesda V\u002FVI ) or core needle biopsy.\n* Single or multiple lesions, each 2.0 cm in maximum diameter.\n* Intrathyroidal tumors (i.e., no extrathyroidal extension, no clinical\u002Fradiological evidence of nodal metastases, nor distant metastases).\n* Lesions located at a safe distance (\\>2 mm) from critical structures (e.g., trachea, esophagus, carotid artery) or accessible with hydrodissection.\n* ≤T1b (i.e. \\\u003C 2cm maximal diameter), N0 or Nx, M0 (no clinical or radiological evidence of lymph node or distant metastasis).\n* Patients unfit for surgery due to comorbidities or who refuse surgery.\n* ≥18 years old\n* Not pregnant at the time of RFA.\n* Able to understand and voluntarily sign informed consent.\n\nExclusion Criteria:\n\n* Evidence of lymph node involvement (clinically or radiologically suspicious or confirmed metastatic nodes) or distant metastasis (e.g., lung, bone).\n* Tumors with extrathyroidal extension\n* Tumors with extensive calcification\n* Tumors located within 2 mm of critical structures where RFA would pose an unacceptably high risk and where hydrodissection is not feasible.\n* Previous thyroid surgery or ablation (RFA, ethanol, laser, or microwave) at the index tumor site.\n* Known diagnosis of anaplastic, poorly differentiated, or other aggressive thyroid cancer variants.\n* Pregnant or breastfeeding at the time of enrollment.\n* Bleeding diathesis or use of anticoagulants that cannot be discontinued safely prior to RFA.\n* Severe comorbid illness that limits life expectancy to less than 5 years.\n* Inability to adhere to study follow-up schedule or procedures or lacking decision-making capacity.\n* Implanted electrical devices such as pacemakers or neurostimulators\n* Infection in the neck including skin infection or thyroiditis at time of planned ablation.\n* Severe cervical anatomy distortion (prior neck surgery or radiation with distorted anatomy that prevents safe RFA","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","This pilot, single-arm clinical study evaluates the feasibility, safety, and effectiveness of radiofrequency ablation (RFA) as a curative treatment for small, low-risk papillary thyroid cancer (PTC). The study will enroll 30 adult patients (≥18 years) with biopsy-confirmed PTC measuring \\\u003C2 cm, who decline surgery or active surveillance, or who are transitioning from active surveillance to active treatment.\n\nEligible participants will undergo ultrasound-guided RFA performed with curative intent at University Health Network. Patients will be followed for up to 12 months with scheduled clinical visits, neck ultrasounds, blood tests, voice assessments, and patient-reported outcome questionnaires. A biopsy of the ablation site at 6-12 months will be used to assess local cancer control.\n\nThe primary objective is to determine the local cure rate and safety profile of RFA for low-risk PTC. Secondary objectives include evaluating post-ablation ultrasound features, patient-reported quality of life, and the feasibility of implementing a multidisciplinary thyroid RFA program within routine clinical practice.\n\nResults from this study will provide important preliminary data to inform future larger trials comparing RFA with surgery and active surveillance for selected patients with low-risk papillary thyroid cancer.",[27],"Thyroid Papillary Carcinoma",[29,30,27,31,32,33],"Thyroid Radiofrequency Ablation","Minimally Invasive Treatment","Ultrasound-guided","Low-risk cancer-focused","Thyroid-sparing","RECRUITING","2026-05-14",{"date":37,"type":38},"2026-05-19","ACTUAL",{"date":40,"type":38},"2026-02-05",{"date":42,"type":21},"2027-07-01",{"name":44,"class":45},"University Health Network, Toronto","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":4,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":5},"100620434","preoperative-prediction-of-lymph-node-metastasis-in-t1n0m0-papillary-thyroid-carcinoma-by-using-contrast-enhanced-ultrasound-100620434","NCT07357571","Preoperative Prediction of Lymph Node Metastasis in T1N0M0 Papillary Thyroid Carcinoma by Using Contrast-enhanced Ultrasound","Multicenter Retrospective Study of Dual-mode Contrast-enhanced Ultrasound Predictive Model for Lymph Node Metastasis Burden in T1N0M0 Papillary Thyroid Carcinoma","Inclusion Criteria\n\n1. Patients with preoperative assessment of T1N0M0 papillary thyroid carcinoma who underwent initial surgical treatment at the medical centers participating in this study between June 2018 and June 2025.\n2. Definitive diagnosis of papillary thyroid carcinoma confirmed by postoperative histopathological examination.\n3. Preoperative conventional ultrasound and contrast-enhanced ultrasound (CEUS) examination of the thyroid and\u002For suspicious central lymph nodes were performed, with complete imaging data of acceptable quality for analysis.\n4. Surgical procedures included thyroidectomy (lobectomy or total thyroidectomy) combined with central lymph node dissection (prophylactic or therapeutic) to provide a definitive pathological gold standard for lymph nodes.\n5. Complete clinical pathological data and imaging data were retrievable from the Hospital Information System (HIS).\n\nExclusion Criteria\n\n1. Preoperative receipt of any anti-tumor treatment targeting the thyroid (e.g., radiotherapy, chemotherapy, targeted therapy, or ablation therapy).\n2. Complication with other types of thyroid malignant tumors (e.g., medullary carcinoma, undifferentiated carcinoma, etc.).\n3. History of neck surgery or radiotherapy that may affect the structure of cervical lymph nodes.\n4. Complication with other systemic diseases that may affect CEUS perfusion characteristics or imaging evaluation (e.g., severe heart failure, liver cirrhosis, etc.).\n5. Allergy to components of the ultrasound contrast agent.\n6. Missing key clinical or imaging data, making complete analysis impossible.",{"count":55,"type":21},600,"OBSERVATIONAL","Similarly, the burden of central lymph node metastasis affects the individualized management of patients with T1N0M0 papillary thyroid carcinoma (PTC): lymph node metastasis is a contraindication to thermal ablation; low-burden lymph node metastasis is suitable for lobectomy; and high-burden lymph node metastasis recommends total thyroidectomy. However, conventional preoperative imaging examinations have low efficacy in diagnosing central lymph node metastasis. This multicenter retrospective cross-sectional study enrolled 600 patients with T1N0M0 PTC who were admitted to our hospital from June 2018 to June 2025 and confirmed by postoperative pathology. Dynamic contrast-enhanced ultrasound (CEUS) images of the thyroid and lymph nodes before surgery were collected for all patients. Two senior ultrasound physicians unaware of the pathological results independently analyzed the images and extracted qualitative and quantitative CEUS features of lesions and suspicious lymph nodes. Taking postoperative pathological results as the gold standard, patients were divided into the high-burden metastasis group, low-burden metastasis group, and non-metastasis group. Univariate and multivariate Logistic regression analyses were used to screen independent predictors, construct a combined predictive model, and draw receiver operating characteristic (ROC) curves and decision curves to evaluate its diagnostic efficacy and clinical practicality. The primary outcome measure was the area under the curve (AUC), and the secondary outcome measures included sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and net benefit. This project is expected to achieve accurate preoperative prediction of the burden of central lymph node metastasis and realize precise and individualized treatment for patients with T1N0M0 PTC.",[27,59],"Contrast Enhanced Ultrasound",[61,62],"thyroid papillary carcinoma","contrast enhanced ultrasound","2026-01-21",{"date":65,"type":38},"2026-01-22",{"date":67,"type":38},"2025-12-01",{"date":69,"type":21},"2026-12-31",{"name":71,"class":45},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University"]